New review of pharmacological therapies for secondary stroke prevention published

A new review has been published that discusses emerging opportunities in the field of secondary stroke prevention.

The authors state: ‘After a minor acute ischemic stroke or transient ischemic attack, patients bear a high cardiovascular risk that is insufficiently addressed by long-term antiplatelet treatment.’  The authors go on to discuss a range of new interventions with the potential to reduce ischaemic stroke recurrence and cardiovascular risk.

The review examines novel antithrombotic, hypolipidaemic, anti-inflammatory, and antidiabetic agents currently undergoing phase II and phase III randomised clinical trials that are likely to reduce the future burden of recurrent stroke. The article also reports on drug regimens that have demonstrated promising results in primary stroke prevention for which further evaluation is warranted.